Literature DB >> 24445601

Advances in NKG2D ligand recognition and responses by NK cells.

Nina Le Bert1, Stephan Gasser1.   

Abstract

The natural killer (NK) group 2 member D (NKG2D) is an activating immune receptor expressed on NK cells, cytotoxic T cells and a subset of other T cells. It has an important role in the recognition and lysis of a variety of infected and tumor cells. Despite significant gains in our understanding of NKG2D, the relevance of NKG2D and its ligands in human diseases has only recently started to emerge. Here, we present an overview of the recent advances in NKG2D biology, discuss the expression of NKG2D ligands in cancer patients and evaluate the diagnostic and prognostic potential of NKG2D ligands.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24445601     DOI: 10.1038/icb.2013.111

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  23 in total

1.  The Human Cytomegalovirus Protein UL148A Downregulates the NK Cell-Activating Ligand MICA To Avoid NK Cell Attack.

Authors:  Vu Thuy Khanh Le-Trilling; Ofer Mandelboim; Liat Dassa; Einat Seidel; Esther Oiknine-Djian; Rachel Yamin; Dana G Wolf
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

2.  NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.

Authors:  David A Sallman; Jason Brayer; Elizabeth M Sagatys; Caroline Lonez; Eytan Breman; Sophie Agaugué; Bikash Verma; David E Gilham; Frédéric F Lehmann; Marco L Davila
Journal:  Haematologica       Date:  2018-04-27       Impact factor: 9.941

Review 3.  NKG2D and its ligands in cancer.

Authors:  Payal Dhar; Jennifer D Wu
Journal:  Curr Opin Immunol       Date:  2018-03-09       Impact factor: 7.486

4.  Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial.

Authors:  Niannian Ji; Neelam Mukherjee; Edwin E Morales; Maggie E Tomasini; Vincent Hurez; Tyler J Curiel; Getahun Abate; Dan F Hoft; Xiang-Ru Zhao; Jon Gelfond; Sourindra Maiti; Laurence J N Cooper; Robert S Svatek
Journal:  Oncoimmunology       Date:  2019-05-25       Impact factor: 8.110

5.  NKG2D-NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo.

Authors:  Saravanan Raju; Lena Z Kretzmer; Olivia I Koues; Jacqueline E Payton; Eugene M Oltz; Amanda Cashen; Bojan Polic; Robert D Schreiber; Andrey S Shaw; Mary A Markiewicz
Journal:  J Immunol       Date:  2016-05-02       Impact factor: 5.422

Review 6.  Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.

Authors:  Katherine Linder; Premal Lulla
Journal:  Hum Vaccin Immunother       Date:  2021-05-03       Impact factor: 3.452

7.  Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients.

Authors:  M Christina Cox; Simone Battella; Raffaella La Scaleia; Sabrina Pelliccia; Arianna Di Napoli; Alessandra Porzia; Francesca Cecere; Eleonora Alma; Alessandra Zingoni; Fabrizio Mainiero; Luigi Ruco; Bruno Monarca; Angela Santoni; Gabriella Palmieri
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

Review 8.  NKG2D Ligands in Tumor Immunity: Two Sides of a Coin.

Authors:  Jinyu Zhang; Fahmin Basher; Jennifer D Wu
Journal:  Front Immunol       Date:  2015-03-04       Impact factor: 7.561

9.  Celiac Disease-Related Inflammation Is Marked by Reduction of Nkp44/Nkp46-Double Positive Natural Killer Cells.

Authors:  Irene Marafini; Ivan Monteleone; Davide Di Fusco; Silvia Sedda; Maria Laura Cupi; Daniele Fina; Alessandro Omero Paoluzi; Francesco Pallone; Giovanni Monteleone
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

10.  T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.

Authors:  Yu-Yang Ng; Johan C K Tay; Zhendong Li; Junjian Wang; Jiangqing Zhu; Shu Wang
Journal:  Mol Ther       Date:  2020-09-05       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.